Literature DB >> 12791214

Animal models of ocular allergy and their clinical correlations.

Margarita Calonge1, Karyn F Siemasko, Michael E Stern.   

Abstract

Ocular allergic diseases represent a wide spectrum of disorders, from the acute self-limited, mild form of seasonal allergic conjunctivitis to the chronic, severe, sight-threatening atopic keratoconjunctivitis. The least problematic forms are the most prevalent, and several animal models have contributed to elucidate their etiopathogenetic mechanisms and have served to test numerous anti-allergic compounds. The most severe and chronic, although less prevalent, ocular allergic problems have not benefited from a similar advance, with the subsequent lack of full understanding and a limited therapeutic armamentarium. Research in this field is currently concentrating efforts in developing more protracted models of ocular allergic inflammation involving the cornea and mimicking more closely the human disease caused by chronic ocular allergy. Most recent experimental models are demonstrating that inhibiting Th2 cells and their secreted cytokines might be one important therapeutic target for inhibiting chronic allergic inflammation in the ocular surface.

Entities:  

Mesh:

Year:  2003        PMID: 12791214     DOI: 10.1007/s11882-003-0097-3

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  44 in total

1.  Pharmacologic modulation of vascular permeability in ocular allergy in the rat.

Authors:  M C Calonge; J C Pastor; J M Herreras; J L González
Journal:  Invest Ophthalmol Vis Sci       Date:  1990-01       Impact factor: 4.799

2.  The ultrastructure of the normal conjunctival epithelium of the guinea pig. III. The bulbar zone, the zone of the fornix and the supranodular zone.

Authors:  S Latkovic
Journal:  Acta Ophthalmol (Copenh)       Date:  1979-04

3.  [Studies on allergic conjunctivitis. 5. Effects of castration and sex hormone administration on experimental allergic conjunctivitis].

Authors:  S Saruya
Journal:  Nippon Ganka Gakkai Zasshi       Date:  1968-07

4.  Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma production in CD4 and CD8 T cells.

Authors:  Susanne J Szabo; Brandon M Sullivan; Claudia Stemmann; Abhay R Satoskar; Barry P Sleckman; Laurie H Glimcher
Journal:  Science       Date:  2002-01-11       Impact factor: 47.728

5.  The role of IL-12 in the induction of late-phase cellular infiltration in a murine model of allergic conjunctivitis.

Authors:  M T Magone; S M Whitcup; A Fukushima; C C Chan; P B Silver; L V Rizzo
Journal:  J Allergy Clin Immunol       Date:  2000-02       Impact factor: 10.793

6.  Histology of ocular late-phase reaction in guinea pigs passively sensitized with IgG1 antibodies.

Authors:  A Leonardi; K J Bloch; R Briggs; M R Allansmith
Journal:  Ophthalmic Res       Date:  1990       Impact factor: 2.892

7.  Properties of guinea pig 7S antibodies. II. Identification of antibodies involved in passive cutaneous and systemic anaphylaxis.

Authors:  Z OVARY; B BENACERRAF; K J BLOCH
Journal:  J Exp Med       Date:  1963-06-01       Impact factor: 14.307

8.  A hapten model of topically-induced ocular anaphylaxis in the rat.

Authors:  S D Trocmé; S Bonini; M C Trocmé; N P Barney; K J Bloch; M R Allansmith
Journal:  Invest Ophthalmol Vis Sci       Date:  1987-02       Impact factor: 4.799

9.  Penetrating the conjunctival barrier. The role of molecular weight.

Authors:  M Kahn; N P Barney; R M Briggs; K J Bloch; M R Allansmith
Journal:  Invest Ophthalmol Vis Sci       Date:  1990-02       Impact factor: 4.799

10.  Atopic keratoconjunctivitis.

Authors:  C S Foster; M Calonge
Journal:  Ophthalmology       Date:  1990-08       Impact factor: 12.079

View more
  1 in total

1.  Topical cis-urocanic acid prevents ocular surface irritation in both IgE -independent and -mediated rat model.

Authors:  Hanna-Mari Jauhonen; Jarmo Laihia; Olli Oksala; Johanna Viiri; Reijo Sironen; Päivi Alajuuma; Kai Kaarniranta; Lasse Leino
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-08-24       Impact factor: 3.117

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.